Tufts Center for the Study of Drug Development, Agilent, Beckman Coulter, NCI, Locus Pharmaceuticals, Biacore, Nonlinear Dynamics, Peakadilly, GeneGo | GenomeWeb

Proteomic Tools Helped Drive 52-Percent Jump in R&D Success at Big Pharma; More Business Likely

Genomic and proteomic technologies have helped to significantly increase the number of drug candidates that enter clinical trials at the world's biggest pharmas, according to a report released last week from the Tufts Center for the Study of Drug Development.

After declining more than 20 percent from the mid-1990s to the early-2000s, the rate at which new drugs entered the clinic increased 52 percent between 1998-2002 and 2003-2005, the report found.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.